LAS VEGAS MEDICAL RESEARCH CENTER

U.S. allows emergency use of Eli Lilly’s COVID antibody therapy

​

Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19

The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus," 

 

Please call if you have symptoms and concern you have covid-19 infection or already tested positive for covid-19.